LAHORE, SEPTEMBER 2018: CCL Pharmaceuticals recently launched MAXFLOW-D – tamsulosin and dutasteride – for Benign Prostatic Hyperplasia (BPH) patients in Pakistan in a ceremony held at a local hotel; this combination is FDA-approved for BPH treatment and it comes with the advantage of once daily dosing. With the launch of MAXFLOW-D, patients now have a more advanced combination treatment option in capsule formulation for moderate to severe BPH symptoms. It is available in the strength of 0.5mg/0.4mg (dutasteride and tamsulosin with HCL) in a pack of 10 capsules.
Benign Prostatic Hyperplasia is as much common as 50% in men of 50 years or older and its incidence increases with increase in age. Dutasteride-containing products are not approved for the prevention of prostate cancer.
It is also not recommended for women of childbearing potential, pediatric patients, patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema, urticaria, pruritus, respiratory symptoms) to dutasteride, other 5-alpha-reductase inhibitors, tamsulosin, or any other component of MAXFLOW-D. Commonly reported adverse effects reported in 1% of subjects are ejaculation disorders, impotence, decreased libido, dizziness, and breast disorders.
For further information please contact Atif Javaid, Business Unit Manager, atif.javaid@cclpharma.com
